Screener
BioCryst Pharmaceuticals BCRX Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total other expense, net | (18,991) | (23,300) | (38,201) | (43,769) |
| Income (loss) before income taxes | 79,474 | 6,486 | (641,334) | 7,244 |
| Income tax expense | 1,079 | 1,401 | 2,083 | 2,127 |
| Net income (loss) | $78,395 | $5,085 | $(643,417) | $5,117 |
| Other comprehensive (loss) income: | ||||
| Foreign currency translation adjustment | (27) | 702 | (89) | 1,068 |
| Unrealized loss on available for sale investments | (133) | (188) | (477) | (343) |
| Total other comprehensive (loss) income | (160) | 514 | (566) | 725 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's net income?
- BioCryst Pharmaceuticals (BCRX) reported net income of $78.4M in Q2 2026.
- How has BioCryst Pharmaceuticals's net income changed year-over-year?
- BioCryst Pharmaceuticals's net income increased by 1441.7% year-over-year, from $5.09M to $78.4M.
- What is the long-term trend for BioCryst Pharmaceuticals's net income?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's net income has grown at a 9.4% compound annual growth rate (CAGR), from -$184.06M to $263.86M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about BioCryst Pharmaceuticals's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude